CRISPR Therapeutics Q2 net loss $208.5M; CASGEVY hits 75 ATCs, 115 cell collections; CTX310 shows 86% LDL reduction

CRISPR Therapeutics AG

2025-Q2 EPS reported -$3.98 revenue$1,757,000

Net loss of $208.5M in Q2 2025 vs $126.4M in Q2 2024; cash & securities $1.72B down from $1.90B at end-2024.
CASGEVY momentum: >75 authorized treatment centers activated, ~115 patients had cells collected, 29 received infusions (16 in Q2).
CTX310 Phase 1 data: dose-dependent TG reduction up to 82% and LDL reduction up to 86% after single administration; full data H2 2025.
EMA authorized Phase 2 trial for SRSD107 (Factor XI siRNA) in thromboembolic disorders; $25M upfront to partner Sirius Therapeutics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.